RIPK3 inhibitors (Ningxia Medical University/Second Military Medical University/Fudan University Shanghai Cancer Center/Fudan University)

N/A

Report date: 2025/01/26 19:35:33
NME

Base Information

Drug NameRIPK3 inhibitors (Ningxia Medical University/Second Military Medical University/Fudan University Shanghai Cancer Center/Fudan University)
Drug Alias NameRIPK3 inhibitors (Ningxia Medical University/Second Military Medical University/Fudan University Shanghai Cancer Center/Fudan University)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase RIPK3 inhibitors
TargetsSerine/threonine-protein kinase RIPK3
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNingxia Medical University
China Registration ClassN/A

Develop Information

Active CompaniesFudan University Shanghai Cancer CenterNingxia Medical UniversityFudan University +[4] 
Inactive CompaniesN/A
Active IndicationsInflammation
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A